Lonza Announces Customer-Dedicated Suites for Commercialization of Bioconjugates
Two new bioconjugation suites to provide high throughput conjugation for the commercialization of antibody-drug conjugates (ADCs) in Lonza’s Ibex®Dedicate 1500m2 of active manufacturing space in addition to established quality control (QC) labs, logistics and other central services Long-term collaboration with Mehr